

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3929456

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS VACCINES AND DIAGNOSTICS INC	06/15/2016
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE BIOLOGICALS SA
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	1330
PROPERTY NUMBERS Total: 6	
Property Type	Number
Patent Number:	6887462
Patent Number:	7399463
Patent Number:	8333958
Patent Number:	7371373
Patent Number:	7892531
Application Number:	13773567
CORRESPONDENCE DATA	
Fax Number:	(610)270-6812
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6102706812
Email:	us_cipkop@gsk.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	VN51585
NAME OF SUBMITTER:	CARLY MORROW
SIGNATURE:	/Carly Morrow/
DATE SIGNED:	06/22/2016

Total Attachments: 3

source=VN51585 GEN Confirmatory Assignment#page1.tif

source=VN51585 GEN Confirmatory Assignment#page2.tif

source=VN51585 GEN Confirmatory Assignment#page3.tif

CONFIRMATORY ASSIGNMENT

WE NOVARTIS VACCINES AND DIAGNOSTICS INC a company duly incorporated in the state of Delaware, and having a registered office at 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States of America do hereby declare that we are the sole owner of the following patents entitled "HSA-FREE FORMULATIONS OF INTERFERON-BETA".

Country	Application Date	Application Number	Grant Date	Patent Number
Australia	26-Oct-01	2002241769	14-Sep-06	2002241769
Austria	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Austria	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Austria	14-Aug-12	SZ34/2012		
Belgium	14-Aug-12	2012C/038		
Belgium	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Belgium	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Bulgaria	26-Oct-01	108322	29-Mar-13	108322
Bulgaria	21-Aug-13	13/029	01-Feb-16	2013/0029
Canada	22-Dec-11	2762966		
Canada	26-Oct-01	2442854	13-Mar-12	2442854
China P R	26-Oct-01	01823122 5	02-May-07	ZL01823122 5
Cyprus	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Cyprus	13-Aug-12	SPC/CY/2012023	21-Apr-15	SPCCY2012023
Czech Republic	26-Oct-01	2003-2735	27-Apr-16	305994
Czech Republic				
Denmark	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Denmark	14-Aug-12	CA201200033		
European Patent Convention	26-Oct-01	01988466 7	15-Feb-12	EP1381432
European Patent Convention	01-Oct-10	10180658 6	26-Feb-14	EP2283897
European Patent Convention	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Finland	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Finland	14-Aug-12	C20120031		
France	26-Oct-01	01988466 7	15-Feb-12	EP1381432
France	14-Aug-12	FR12C0050		
France	01-Oct-10	10180658 6	26-Feb-14	EP2283897
France	01-Oct-10	10180630 5	03-Sep-14	EP2283896
United Kingdom	01-Oct-10	10180630 5	03-Sep-14	EP2283896
United Kingdom	01-Oct-10	10180658 6	26-Feb-14	EP2283897
Germany	14-Aug-12	122012000058 6		
Germany	01-Oct-10	10180658 6	26-Feb-14	60148621 8
Germany	01-Oct-10	10180630 5	03-Sep-14	60148992 6
Germany	26-Oct-01	01988466 7	15-Feb-12	60146134 7
Greece	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Hungary	17-Sep-13	S1300051/1		
Hungary	26-Oct-01	P0303732	21-Mar-13	228581


Ireland	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Ireland	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Ireland	14-Aug-12	2012/032		
Israel	26-Oct-01	157963	30-Nov-13	157963
Italy	13-Aug-12	UB2012P001258	04-Jan-13	0000001258
Italy	01-Oct-10	502014000002511	03-Sep-14	EP2283896
Italy	01-Oct-10	502014902259200	26-Feb-14	EP2283897
Italy	26-Oct-01	502012902023053	15-Feb-12	EP1381432
Japan	07-Jul-08	2008-177303	18-Jul-14	5580521
Japan	26-Oct-09	2009-245975		
Japan	15-Jan-13	2013-004395	27-Feb-15	5701323
Japan	11-Dec-14	2014-250577		
Korea South	26-Oct-01	10-2003-7013202	27-May-09	10-0900753
Luxembourg	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Luxembourg	14-Aug-12	92060	15-Oct-12	92060
Monaco	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Netherlands	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Netherlands	01-Oct-10	10180658 6	26-Feb-14	EP2283897
Netherlands	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Netherlands	14-Aug-12	300546		
Norway	26-Oct-01	20034492	14-Mar-11	330259
Poland	26-Oct-01	P366790	06-Jul-12	213297
Poland	08-Jan-13	22619/SPC/13		
Portugal	14-Aug-12	1000063104	12-Feb-13	496
Portugal	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Portugal	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Switzerland	01-Oct-10	10180658 6	26-Feb-14	EP2283897
Switzerland	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Switzerland	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Switzerland	14-Aug-12	C01381432/01	30-Jun-15	C01381432/01
Singapore	26-Oct-01	200305956-5	31-Jul-06	99664
Spain	01-Oct-10	10180630 5	03-Sep-14	EP2283896
Spain	01-Oct-10	10180658 6	26-Feb-14	EP2283897
Spain	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Spain	13-Aug-12	C201200033		
Sweden	26-Oct-01	01988466 7	15-Feb-12	EP1381432
Sweden	14-Aug-12	1290029-6		
Turkey	01-Oct-10	2014/14575	03-Sep-14	TR201414575
Turkey	26-Oct-01	2012/01915	15-Feb-12	TR201201915
United States	25-Oct-01	10/035397	03-May-05	6887462
United States	09-Apr-04	10/821333	15-Jul-08	7399463
United States	11-Jan-11	13/004658	18-Dec-12	8333958
United States	18-Feb-05	11/062146	13-May-08	7371373
United States	09-Apr-08	12/082177	22-Feb-11	7892531
United States	21-Feb-13	13/773567		

Whereas in accordance with the Patent Assignment Agreement dated 26 February 2015 between **NOVARTIS VACCINES AND DIAGNOSTICS INC** and **NOVARTIS AG**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS VACCINES AND DIAGNOSTICS INC** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **NOVARTIS AG** of Lichtstrasse 35, 4056 Basel, Switzerland

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS AG** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS AG** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium

Dated this 15 day of June 2016

Signed for and on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC




Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC



Theodore R. Furman
Authorized Signatory on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC

Signed for and on behalf of
NOVARTIS AG




Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS AG



Theodore R. Furman
Authorized Signatory on behalf of
NOVARTIS AG

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA



William R. Majarian
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA